Executives said at the STAT Summit there is a lot of exploring left to do in pairing Keytruda with personalized mRNA vaccines, as Moderna shares swung on the me

The pullback followed a sharp run-up in Moderna stock tied to optimism over its mRNA cancer vaccine program.

The revamped approach is intended to give developers and investors more predictability in weighing approval chances for rare disease therapies.

The drop treats age-related near-vision loss, which affects roughly 90% of U.S. adults over 45.

The Biogen-backed startup, led by RA Capital, will fund two genetic medicines for the inherited kidney disorder ADPKD.

CEO Tom Miller discussed the roadshow and how AI's role in drug development is evolving after the offering.

The Phase 3 result is a notable efficacy signal for an antisense therapy in amyotrophic lateral sclerosis.

The approval creates a self-administered option for a condition previously requiring clinic-based treatment.

The CD19/CD20 candidate is designed to generate immune cells inside the body rather than through ex vivo manufacturing.

The early data covers a rare skin cancer indication with few effective options.

The company reported encouraging early results from a study of more than 200 patients with advanced solid tumors.

European regulators recommended approval of Rasonque after a prior FDA green light.

The largely unregulated injections have been favored by Health Secretary Robert F. Kennedy Jr.

The label expansion broadens the approved use of the immunotherapy in bladder cancer.

The Belgian startup, chaired by former Galapagos CEO Paul Stoffels, takes over cell therapies divested in a strategic overhaul.

Proceeds will support three medicines in or nearing clinical testing and earlier work on RNAi treatments for tissues outside the liver.

The results set a new standard for the fast-moving amylin-based obesity drug field.

The finding points to a potential target for improving responses to cancer immunotherapy.